Bondoufle, France

Marie-Odile Galcera-Contour

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2010-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Marie-Odile Galcera-Contour: Innovator in Cancer Treatment

Introduction

Marie-Odile Galcera-Contour is a prominent inventor based in Bondoufle, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of novel compounds. With a total of 2 patents, her work focuses on inhibitors of cdc phosphatases, which play a crucial role in cancer therapy.

Latest Patents

Her latest patents include groundbreaking inventions that target cdc25 phosphatases. The first patent describes novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units. These compounds are designed to inhibit cdc25-C phosphatase, which is particularly relevant in the treatment of cancer. The second patent focuses on 4,7-dioxobenzothiazole-2-carboxamide derivatives, which also inhibit cdc25 phosphatases, specifically cdc25-C phosphatase, and can be utilized in cancer treatment.

Career Highlights

Marie-Odile Galcera-Contour is currently associated with Ipsen Pharma S.a.s., where she continues her research and development efforts. Her work has been instrumental in advancing therapeutic options for cancer patients.

Collaborations

She collaborates with notable colleagues, including Grégoire Prevost and Alban Sidhu, to further enhance the impact of her research in the pharmaceutical industry.

Conclusion

Marie-Odile Galcera-Contour's innovative contributions to cancer treatment through her patents highlight her role as a leading inventor in the field. Her work continues to pave the way for new therapeutic approaches that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…